Pharmaceuticals & Therapeutics

New data shows a national drop in overdose deaths, but a closer look reveals a fractured reality with regional surges and a dangerous new drug cocktail.

Amid a venture capital slowdown, a Philadelphia model is gaining traction by prioritizing discipline over hype. We explore how this ecosystem is making startups investor-ready.

Biocytogen's new 'gold standard' accreditation isn't just about animal welfare. It's a calculated move to de-risk drug development and win global partners.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

A new partnership between cliexa and OpiSafe integrates predictive AI with patented workflow tools, promising to reshape opioid stewardship from within the EMR.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?

Formerly Hoth Therapeutics, Rocket One is betting its future on novel spintronic computing. A look at the tech, the risks, and the ambitious strategy.

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

As climate change fuels record dengue outbreaks across Asia, a new six-nation pact aims for 'Zero Deaths.' But can it overcome the gap between innovation and reality?

A new partnership between Argonaut and Ensera aims to untangle complex supply chains for drug-device products, potentially leveling the field for smaller innovators.

With UK approval for its EURneffy 1 mg nasal spray, ALK is set to disrupt the pediatric anaphylaxis market by offering a game-changing needle-free alternative.

Susan Solomon’s Tang Prize is more than an award; it's a tale of how science can save us, and a stark reminder of the irreversible challenges ahead.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A single bottle of Yamazaki 50-Year-Old just sold for HK$8.25M, shattering records. We deconstruct why this isn't just about whisky, but a seismic shift in luxury investing.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.